10/09/2020 - 08:54

PharmAust drug impacts COVID-19 in ‘every experiment’

10/09/2020 - 08:54

Bookmark

Save articles for future reference.

ASX-listed clinical-stage oncology group, PharmAust, continues to show that its cancer fighting drugs, Monepantel and Monepantel Sulfone, can have a positive, anti-viral effect on cultured cells that are infected with the Coronavirus. According to the Perth-based company, a second repeat of its in-vitro anti-viral confirmatory testing successfully demonstrated the anti-COVID-19 activity of both Monepantel and Monepantel Sulfone.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options